Mazdutide dosage in published studies and labels

These are the doses used for Mazdutide in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Mazdutide has no FDA-approved dosage. Human dosing comes from phase 3 trials in Chinese adults with overweight or obesity. GLORY-1 compared 4 mg and 6 mg injected under the skin once a week with placebo for 48 weeks, with mean weight changes of -11.0% and -14.0% against +0.3%, and GLORY-2 tested 9 mg weekly for 60 weeks, with -16.7% against -1.5%.

Clinical Trial Evidence

Dosage evidence summary for Mazdutide
Human dosing established	Yes
Studied dose range	4–9 mg once weekly in phase 3 trials
Route	Subcutaneous
Frequency	Once weekly
Duration studied	48–60 weeks in the published phase 3 trials
Evidence level	Clinical Trial Evidence
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Mazdutide, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
GLORY-1 — phase 3, NEJM 2025 (NCT05607680)Clinical trial · Randomized, double-blind, placebo-controlled phase 3 trial	Chinese adults with obesity, or overweight with a weight-related condition (n=610)	4 mg or 6 mg	Subcutaneous	Once weekly	48 weeks	Mean body-weight change at week 48: -11.0% (4 mg), -14.0% (6 mg), +0.3% (placebo)	Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight. N Engl J Med. 2025.
GLORY-2 — phase 3, JAMA 2026 (NCT06164873)Clinical trial · Randomized, double-blind, placebo-controlled phase 3 trial	Chinese adults with obesity (461 analysed)	9 mg	Subcutaneous	Once weekly	60 weeks	Mean body-weight change at week 60: -16.7% vs -1.5% with placebo	Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. JAMA. 2026.

Where sources disagree

Both phase 3 trials enrolled Chinese adults only. The FDA has not approved mazdutide, and these trial doses are not an approved dosage in the United States.
Like other drugs in this class, mazdutide is a weekly injection whose doses are trial arms, not interchangeable with doses of semaglutide, tirzepatide or retatrutide.